Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aspirin vs Placebo in Clinical High Risk for Psychosis
NCT02047539Phase 1Terminated
- Sponsor
- Yale University
- Start
- Jan 2015
- Primary completion
- Mar 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of aspirin in Clinical high risk for psychosis (CHR) (2 arms), sponsored by Yale University. Primary endpoint: Scale of Prodromal Symptoms at 12 weeks. Started Jan 2015; status: terminated.
02
Drugs
aspirin
03
Conditions
Clinical high risk for psychosis (CHR)
Beyond the preview
Go deeper on NCT02047539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02047539.